
    
      This study will enroll 150 moderately severe to severe Alzheimer's disease subjects. Subjects
      will be randomly assigned 1:1:1 to treatment with two different doses of bryostatin 1 or
      placebo. The primary analysis will take place after 12 weeks of treatment (7 doses).
    
  